- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02474992
The Kanyakla Study: a Microclinic Social Network Intervention for Promoting Engagement and Retention in HIV Care
August 7, 2019 updated by: University of California, San Francisco
The purpose of this randomized controlled trial is to compare a social network-based behavioral intervention known as microclinics to standard HIV clinical care alone in helping patients receiving HIV care on Mfangano, Remba and Ringiti Islands, Kenya remain adherent to clinic appointments.
The study is designed to evaluate the effectiveness of microclinics on reducing gaps in clinical care, HIV viral load and HIV-related stigma, compared to standard HIV clinical care alone.
By doing this research study, the investigators hope to learn whether microclinics are a useful social strategy for improving delivery of HIV treatment in rural Kenya.
Study Overview
Study Type
Interventional
Enrollment (Actual)
304
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Homa Bay County
-
Mfangano Island, Homa Bay County, Kenya
- Ekialo Kiona Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
Must be currently receiving combination antiretroviral therapy (cART) or co-trimoxozole prophylaxis from one of the eligible study clinics:
- Is currently in care at study baseline, defined as having ≥1 medical care visit to receive medications (cART or prophylaxis) during the six months preceeding initiation of study enrollment, OR
- Initiates pre-ART or ART care for the first time at a study clinic during the six month study recruitment period, OR
- Transfers from a clinic outside the study area and receives pre-ART or ART care for the first time from a study clinic during the six month recruitment period
- Participants become eligible for study inclusion on the 4th day following a missed clinic appointment, provided the patient has not transferred care to another clinic prior to the 4th day, moved outside the study area or died. Participants who miss a study visit by >3 days but return to clinic before recruitment takes place are still eligible for study enrollment. Missed visits must have occurred within the previous 90 days at the time of eligibility assessment to meet this inclusion criteria.
- Must currently reside on Mfangano, Remba or Ringiti Island.
- Must be conversant with one of the commonly spoken languages within the study area (i.e. DhoLuo, Swahili or English; prior experience indicates that this represents >99% of the adult population).
- Must be ≥18 years of age as of the date of study eligibility.
Exclusion Criteria:
- Eligible participants who reside in the Mfangano East sub-location will be excluded from participation in this study. Many of these patients have already participated in the microclinic intervention as part of the Mfangano Island Healthy Network Impact Study.
- Participants planning on moving permanently out of the study area within the next six months will be excluded.
- Participants who, should they be randomized to the intervention arm, would be unwilling to participate in a microclinic will be excluded from study enrollment.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Intervention
This arm is eligible for participation in the Microclinic intervention, a social network-based educational program.
|
Individuals randomized to this arm will be invited to recruit members of their social network to form a health team, or microclinic.
These groups will proceed through a discussion-based health education curriculum led by local community health workers.
Topics will include HIV biology, medications, the importance of social support, and community outreach for reducing HIV stigma.
The curriculum will conclude with an opportunity for all group members to disclose their HIV status to one another.
Other Names:
|
|
No Intervention: Comparison
This arm is not eligible for participation in the intervention during the first twelve months of the study.
Following collection of the primary study endpoints, this arm will also be invited to participate in a Microclinic group.
Participants in this arm will still have access to standard HIV care at the facility of their choice.
At time of recruitment into the study, prior to randomization, all eligible participants will be counseled on the importance of returning to their clinic for ongoing HIV care.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Disengagement from care
Time Frame: 12 months
|
Incidence of 90-day absence from care following a missed appointment
|
12 months
|
|
Disengagement from care
Time Frame: 12 months
|
Proportion of time eligible for HIV care that patient is adherent to clinic appointment schedules.
Calculated by subtracting the sum of all gaps in care from the total time eligible for care, and dividing by total time eligible for care.
Gaps in care are defined as the number of days between a missed appointment and subsequent return to any clinic in the study area to access HIV care.
|
12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Virologic suppression
Time Frame: 12 months
|
Proportion of patients who are virologically suppressed 12 months after randomization
|
12 months
|
|
HIV-related stigma
Time Frame: 12 months
|
Reduction in stigma as compared to baseline, measured by the Earnshaw HIV Stigma Framework
|
12 months
|
|
Re-engagement in care
Time Frame: 12 months
|
Incidence of re-engagement in care following missed visit at time of study enrollment
|
12 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Elizabeth A Bukusi, MBChB, M.Med, PhD, Kenya Medical Research Institute
- Principal Investigator: Matthew D Hickey, MD, University of California, San Francisco
- Principal Investigator: Charles R Salmen, MD, MPhil, Organic Health Response
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 2016
Primary Completion (Actual)
June 1, 2019
Study Completion (Actual)
June 1, 2019
Study Registration Dates
First Submitted
June 16, 2015
First Submitted That Met QC Criteria
June 16, 2015
First Posted (Estimate)
June 18, 2015
Study Record Updates
Last Update Posted (Actual)
August 8, 2019
Last Update Submitted That Met QC Criteria
August 7, 2019
Last Verified
August 1, 2019
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- OHR006
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HIV
-
Duke UniversityGilead SciencesRecruitingHIV Prevention | HIV Pre-exposure Prophylaxis | HIV Prevention Program | HIV Prevention and Care | HIV Pre-exposure Prophylaxis UseUnited States
-
University of Alabama at BirminghamMobile County Health Deparment; Alabama Department of Public HealthRecruitingHIV | HIV Testing | HIV Linkage to Care | HIV TreatmentUnited States
-
University of Alabama at BirminghamNational Institute of Mental Health (NIMH)RecruitingPrEP | HIV | HIV Prevention | PrEP UptakeUnited States
-
Institute of HIV Research and Innovation Foundation...National Institutes of Health (NIH)RecruitingHIV Prevention | PrEP Adherence | HIV Related StigmaThailand
-
French National Agency for Research on AIDS and...Elizabeth Glaser Pediatric AIDS FoundationCompletedPartner HIV Testing | Couple HIV Counseling | Couple Communication | HIV IncidenceCameroon, Dominican Republic, Georgia, India
-
Massachusetts General HospitalNational Institute of Mental Health (NIMH)RecruitingFeasibility | HIV Prevention | PrEP Uptake | Acceptability | HIV Self-testing | Male Partners of HIV-negative Postpartum WomenSouth Africa
-
ANRS, Emerging Infectious DiseasesHopital Universitaire Robert-Debre; Institut de Recherche pour le Developpement and other collaboratorsUnknownHIV | HIV-uninfected Children | Children Exposed to HIVCameroon
-
University of MinnesotaWithdrawnHIV Infections | HIV/AIDS | Hiv | AIDS | Aids/Hiv Problem | AIDS and InfectionsUnited States
-
University of PennsylvaniaNational Institute of Mental Health (NIMH); University of BotswanaRecruitingPregnancy | HIV | Post-partum | HIV Antiretroviral Therapy (ART) AdherenceBotswana
-
Johns Hopkins UniversityNational Institute of Mental Health (NIMH)RecruitingHIV Prevention | HIV Risk Behavior | HIV Counseling and TestingUnited States
Clinical Trials on Microclinic
-
Microclinic InternationalMinistry of Health Jordan; Royal Health Awareness Society (RHAS), JordanCompleted
-
Microclinic InternationalBell County Department of Health, KentuckyCompletedHypertension | Obesity | Dyslipidemia | Heart Disease | Diabetes Mellitus, Type IIUnited States
-
Microclinic InternationalHarvard School of Public Health (HSPH); Qatar University; Qatar Foundation; Qatar... and other collaboratorsCompletedHypertension | Overweight and Obesity | Diabetes Mellitus, Type II | Behavioral Lifestyle Change | Social ChangeQatar
-
University of California, San FranciscoKenya Medical Research Institute; Organic Health Response; Microclinic InternationalCompleted
-
University of California, San FranciscoKenya Medical Research Institute; Organic Health Response; Microclinic InternationalCompleted
-
Microclinic InternationalRoyal Health Awareness Society (RHAS); Jordanian Ministry of Health (MoH)CompletedHyperglycemia | Hypertension | Obesity | Diabetes Mellitus, Type 2 | Diabetes Mellitus | Diabetes | Body Weight | Weight Loss | Blood Pressure | Weight Gain | Social Behavior | Weight, Body | Glucose, High Blood | Lifestyle, Healthy | Weight Change, Body | Behavior, Health | Lifestyle Risk Reduction | Blood Pressure, High | Hyperglycaemia... and other conditionsJordan